What are grey-market peptides, and where do they come from?

Somebody in a group chat says they got their tirzepatide from a "grey market" vendor and everyone nods like that clears things up. It doesn't, not really. There's no grey-market storefront with a sign out front, no single supply chain everyone uses, and no regulator whose job is to define the term for you. It's a description that grew up around a real product category (you'll see it spelled "gray market" too; it's the same thing), and it's worth taking apart.

This is the boring-but-necessary part before anything else on this site makes sense: what the label on the vial means, who tends to make the thing inside it, why so many more people are buying it now than three years ago, and what the law actually says. No sourcing advice, no vendor names, no "here's how to get it." Just the shape of the market.

"Research use only" is a label, not a guarantee

Peptides sold this way almost always ship with "for research use only," "not for human consumption," or similar language on the vial or the listing. That phrase is doing legal work, not safety work. It signals that the seller is not claiming the product is a drug, a supplement, or approved for use in a human body — which, under U.S. law, keeps the sale in a very different regulatory lane than a pharmacy would occupy.

It says nothing about what's actually in the vial. A "research use only" label does not mean the compound was made in a facility with quality controls, does not mean anyone checked its identity or purity before it shipped, and does not mean the person buying it is, in fact, a researcher. In practice, most buyers in this market are not running a study. They're using the compound the same way they'd use a prescription version of it. The label is the thing that lets that transaction happen outside the systems built to catch it.

That's the core of why this site exists: the label tells you about the seller's legal posture, not about the vial's contents. Only a lab report can speak to the second part, and even that has limits we get into elsewhere.

Where the compound actually comes from

Peptide manufacturing is a real, specialized industry, and most of the volume behind grey-market products traces back to China. According to reporting by ChinaTalk, Guangdong province is home to roughly 70% of the country's cosmetic-peptide manufacturers, with Shandong, Shaanxi, and Henan as other production centers. Some are large, sophisticated contract manufacturers serving the pharmaceutical industry. Others are smaller synthesis shops that sell directly to overseas buyers, sometimes under several brand names at once.

U.S. import data reflects the growth: According to U.S. Customs data cited by ChinaTalk, American imports of hormone and peptide compounds from China roughly doubled to $328 million in the first three quarters of 2025, up from $164 million in the same period of 2024. In 2024, China's National Medical Products Administration announced it had busted three illicit distributors of injectable semaglutide, with cases escalated to criminal prosecution. ChinaTalk reports the largest buyer base for Chinese peptides is the U.S., followed by Canada, Australia, and Latin America.

From the manufacturer, the path to a buyer typically runs through one or more resellers: storefronts, pooled-order organizers, or "kit" sellers who repackage bulk material into individual vials, sometimes adding their own labels and sometimes their own (unverified) certificates of analysis. This is a meaningful distinction we cover in more depth elsewhere: whether a seller is close to the manufacturing, or several steps removed from it, changes what they can honestly know about their own product. A reseller further down the chain often has no more insight into what's actually in the vial than the buyer does.

Why demand exploded

The proximate cause is price. Branded GLP-1 medications — semaglutide and tirzepatide, sold under names most people now recognize — list in the hundreds of dollars a month without insurance coverage, and coverage itself is inconsistent. Compounding pharmacies offered a cheaper legal alternative for a while, filling prescriptions with the same active ingredients during a period when the brand-name drugs were in short supply. That mattered because nearly three-quarters of American adults are classified as overweight or obese, while only about 8% report having taken a weight-loss medication, according to KFF research cited by Reuters — a huge gap between people who might benefit and people who are on a prescription.

Then the shortage that justified compounding eased: FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then set deadlines for compounders to stop, closing off the legal cheap option for a lot of people who had come to depend on it. Reuters and other outlets have documented what happened next: buyers moved to sourcing the raw ingredients themselves, sometimes from the same category of overseas suppliers that already served the "research peptide" hobbyist and bodybuilding markets for compounds like BPC-157 and TB-500. One community following this pattern, a Telegram group called StairwayToGray, had more than 21,000 members and was gaining nearly 1,000 a week, and Reuters reported that shipments of active ingredients from Chinese entities not registered with the FDA jumped 44% in January 2025 from the previous month. A woman profiled in that coverage described spending about $50 a month on self-sourced material versus an expected $500 a month through the manufacturer's official channels.

This is also where the market crosses into cryptocurrency in a way that's worth knowing about, even without getting into how anyone pays for anything. Traditional banks and payment processors generally won't touch sales of unapproved compounds represented as being for human use, so the money side of this market has moved increasingly on-chain. Chainalysis, which tracks cryptocurrency flows, said the on-chain grey-market peptide economy was on pace to process $39 million in the second quarter of 2026, a run rate above $100 million a year, up from about $200,000 a month before its viral breakout. Their report also flagged something uncomfortable: some chemical suppliers had recently pivoted away from supplying fentanyl and amphetamine precursors to transnational drug cartels toward this newer, faster-growing consumer category.

None of that tells you anything about a specific vial. It's context for why the shelf got so much bigger, so fast.

The legal and regulatory picture, stated carefully

This is not legal advice, and the rules are genuinely unsettled in places. Here's what's documented.

The FDA does not approve "research use only" peptides for human use, by definition — that's what the label is avoiding claiming. In September 2025, according to a legal analysis by Health Law Alliance, the agency sent more than 50 warning letters to compounding operations, some for marketing compounded GLP-1 drugs as "generic versions" of approved products, and separately to sellers whose "research use only" labeling didn't match advertising that clearly targeted human use — BPC-157 was one of the compounds named. The FDA also created an import alert aimed at intercepting GLP-1 active ingredients with quality concerns at the border, and increased inspections of foreign manufacturing sites.

U.S. Customs and Border Protection has intercepted shipments directly. In one release, the Cincinnati field office described intercepting roughly 5,000 individual peptide packages — including retatrutide, semaglutide, tirzepatide, and other compounds like MOTS-C and cagrilintide — hidden inside more than 300 mis-manifested master cartons shipped from China between December 2025 and March 2026, each carton concealing around 15 unlabeled inner packages addressed to individual recipients.

Enforcement intensity has also varied over time. We're not going to speculate about future enforcement. What's true right now is that these compounds sit outside FDA approval for human use, and both the FDA and CBP have taken visible action against parts of this supply chain in the past year.

A quick glossary, because the jargon is half the barrier to entry

Every corner of this market has its own shorthand, and it trips up newcomers as much as anything technical does. "Tirz" is tirzepatide; "reta" is retatrutide, sometimes called "GLP-3" informally even though that's not an official drug class name; "sema" is semaglutide. "Source" means a vendor, and "sourcing" means getting product from one — a euphemism that itself tells you something about how aware this community is of its own legal footing. A "group order" (also called a pooled order) is a batch of purchases combined together, sometimes for a volume discount, sometimes specifically to fund shared lab testing on that batch. "COA" is certificate of analysis, the lab document at the center of most of this site. "Endo" is short for endotoxin. And "exit scam" describes a vendor that builds up a reputation, takes a wave of orders, and disappears without shipping — a real and recurring pattern in unregulated markets with no chargeback protection or regulatory recourse.

Knowing the vocabulary doesn't make anything safer, but it does make it possible to read the community discussion — and the lab reports — accurately instead of guessing at what a thread is actually claiming.

What the numbers actually look like, compound by compound

It's worth being concrete about scale rather than talking about "the market" as one undifferentiated thing. In our database as of September 28, 2026, tirzepatide alone accounts for 788 of the 1,527 total vials tested — by far the largest single category — followed by retatrutide at 336. Everything else is smaller: BPC-157 (41), tesamorelin (32), GHK-Cu (29), NAD+ (28), MOTS-C (22), TB-500 (22), ipamorelin (20), semaglutide (18), SS-31 (17), and epitalon (16) are the only other compounds with 15 or more tested vials, enough to start seeing a pattern. That concentration in GLP-1-adjacent compounds tracks pretty directly with the pricing story above: tirzepatide and retatrutide are the compounds people are most often trying to source cheaply as an alternative to expensive branded prescriptions, so they're also the ones buyers test most often.

The quality problem nobody selling you the vial has an incentive to fix

Strip away the legal question and there's a separate, practical one: even if you accept the legal risk, does the vial contain what the listing says?

Nobody in the standard sales chain is required to answer that. There's no FDA inspection, no pharmacy verification, no batch release testing that a regulator checks. Individual buyers who commission their own independent lab testing are, in a real sense, the only quality control this market has. That's the gap this site is built to fill: VendorVerify aggregates reports from independent labs, most of them paid for by buyers themselves — Janoshik above all, along with Peptide Test/TrustPoint, Freedom Diagnostics, Chromate, and others — and turns them into a per-vendor track record. As of September 30, 2026, our database holds 1,529 results from 67 vendors, going back to March 2023. We don't test anything ourselves, we don't accept a vendor's own certificates, and we don't take money from vendors. When a vendor paid an independent lab itself, that report is labeled and counts at half weight.

The community has also organized its own version of this at scale for years, through group testing: a batch's buyers pool money to send a handful of vials to a lab like Janoshik and split the cost, sometimes bringing per-person testing fees down to around $10, according to the Gray Market Substack. It works, but it's ad hoc — it depends on enough buyers caring enough to organize, so smaller vendors and less popular compounds often go untested for long stretches. Chainalysis estimates that independent testing spending per buyer fell about 88% to roughly $8 as the market pulled in more casual buyers who rely on vendor-provided certificates, even as total testing volume rose about sixfold, which is its own kind of warning sign.

What this means if you're trying to understand the market, not just find a product

If you take one thing from this piece, it's that "grey market" describes a legal and structural position, not a quality tier. Some vials tested this way come back clean; some don't, and the failure modes vary by compound and by how many hands the product passed through before it reached a buyer. We break down what independent lab data can and can't tell you about safety in a companion piece, and look specifically at what's known — and not known — about testing outcomes tied to Chinese manufacturing in another. If you're trying to read an actual certificate of analysis rather than take a listing's word for it, start here. Neither one is a substitute for understanding what you just read here: this is an unregulated market, running mostly on trust between strangers, with real legal exposure and no guaranteed quality floor. For research use only, on paper. In practice, judged one lab report at a time.

Database figures without a date update automatically from VendorVerify's database of independently commissioned lab reports; dated figures are snapshots. Live, per-vendor numbers are on our vendor ratings page; our methodology explains how reports are scored.